Molecular tumor board: the University of California-San Diego Moores Cancer Center experience. - Wikidata - awgldk - TriplyDB

Molecular tumor board: the University of California-San Diego Moores Cancer Center experience.

Molecular tumor board: the University of California-San Diego Moores Cancer Center experience.

http://www.wikidata.org/entity/Q33699594

about

Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications The possibility of clinical sequencing in the management of cancer An NGS Workflow Blueprint for DNA Sequencing Data and Its Application in Individualized Molecular Oncology.Integrating Genomics Into Clinical Pediatric Oncology Using the Molecular Tumor Board at the Memorial Sloan Kettering Cancer Center.Clinical Implementation of Integrated Genomic Profiling in Patients with Advanced Cancers.Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery.Clinical sequencing using a next-generation sequencing-based multiplex gene assay in patients with advanced solid tumors.Dramatic response to dabrafenib and trametinib combination in a BRAF V600E-mutated cholangiocarcinoma: implementation of a molecular tumour board and next-generation sequencing for personalized medicine.Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA Effective quality management practices in routine clinical next-generation sequencing.Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines.Implementation of a Molecular Tumor Board: The Impact on Treatment Decisions for 35 Patients Evaluated at Dartmouth-Hitchcock Medical Center.Next generation sequencing demonstrates association between tumor suppressor gene aberrations and poor outcome in patients with cancer "A rising tide lifts all boats": establishing a multidisciplinary genomic tumor board for breast cancer patients with advanced disease.Single-Center Experience with a Targeted Next Generation Sequencing Assay for Assessment of Relevant Somatic Alterations in Solid Tumors.Molecular Tumor Boards: Ethical Issues in the New Era of Data Medicine.Targeting the undruggable: immunotherapy meets personalized oncology in the genomic era.Molecular inimitability amongst tumors: implications for precision cancer medicine in the age of personalized oncology.Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay "He Beat You in the Blood": Knowledge and Beliefs About the Transmission of Traits Among Latinos from Mexico and Central America Clinical Outcomes of Patients with Rare and Heavily Pretreated Solid Tumors Treated according to the Results of Tumor Molecular Profiling.Use of dedicated gene panel sequencing using next generation sequencing to improve the personalized care of lung cancer.Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy.Gene expression profiling for targeted cancer treatment.The changing landscape of phase I trials in oncology.Key Lessons Learned from Moffitt's Molecular Tumor Board: The Clinical Genomics Action Committee Experience.Exceptional Response to Nivolumab and Stereotactic Body Radiation Therapy (SBRT) in Neuroendocrine Cervical Carcinoma with High Tumor Mutational Burden: Management Considerations from the Center For Personalized Cancer Therapy at UC San Diego Moores Immunogenomics: using genomics to personalize cancer immunotherapy.Clinical Implementation of Novel Targeted Therapeutics in Advanced Breast Cancer.A Network of Conserved Synthetic Lethal Interactions for Exploration of Precision Cancer Therapy.The ins and outs of molecular pathology reporting.Multidisciplinary Care.Use of comprehensive genomic profiling to direct point-of-care management of patients with gynecologic cancers.The fuzzy world of precision medicine: deliberations of a precision medicine tumor board.Implementation and utilization of the molecular tumor board to guide precision medicine.Comprehensive genomic profiling in routine clinical practice leads to a low rate of benefit from genotype-directed therapy.Actionability and precision oncology.Molecular Tumor Boards: Current Practice and Future Needs.Molecular Tumor Boards: Realizing Precision Oncology Therapy.Bioinformatics for precision oncology.

P2860

Q26801718-4724C7D8-32A2-4E81-8014-91436D66A145 Q28072144-A26F02F9-7392-4A9B-86DA-FB7FAE3049E9 Q31077769-3802DED2-E2CC-4E0B-A89A-637E1AC9A699 Q33677392-D91B63DC-FA0C-47E1-9CF7-A1A6B28BE1D4 Q33685000-5739BB46-936C-40BA-ACC4-C8E4E60D9669 Q33688966-6487EB83-93D1-439B-93FC-53032FDB4254 Q33873653-E8C0D235-F10B-4839-83B9-6B04B1BCDD3F Q34550326-66AF7622-0DBE-42F6-81BA-250FBF8F7340 Q35810461-B92E1EA4-DA80-4C08-A486-8A8201082D3D Q35922622-A278AEDB-8499-4215-B107-79394CDA3C57 Q36021163-7E4008C0-DC70-435F-8CA2-3BB6D092EB82 Q36064946-89F9DF71-7ED5-43FF-8589-ABFEF403B30E Q36188758-4E27BA63-6C9B-491B-8C1A-13F6C7D6121D Q36200285-590F8DA0-C8D3-4511-A1C2-3ADF2DF6B9C6 Q36270828-9FA027E2-D1C3-412B-9C08-28F9A912413F Q36303802-C3536DC6-0BBB-4527-BB4A-F29F4FAACB95 Q36316627-2A889626-EB84-43C8-98DE-D81AA91ACF92 Q36544915-4FC3056D-F433-4A7E-B6C9-CB2B7F3A7BAD Q36962764-969A6A81-632C-4197-AC77-3036A8111C7A Q36994949-0B1D6FC2-515D-48DC-90C9-A9D1177E9087 Q37150582-A5B5C665-0293-4D7F-8041-97CBE6E114B5 Q37269473-867C79D5-C0AC-4CE3-B15B-686A82B9389D Q37482015-00B0D9F9-526C-4BF2-A113-46159A3EB9B0 Q38259249-F89592AF-00D3-47D4-9AB1-923A52B9758A Q38629203-C91D76B6-30CB-41E0-9B83-942C81651358 Q38759643-EFD1CB33-7AA4-4682-B79B-0036B97D9528 Q38760780-96965B0A-E5D5-4D61-BE7E-7729702FEFA9 Q38772744-6C4B3C4D-1FD3-4B91-B9AB-C83A9B6050D9 Q38825945-9A62353E-C15D-40C1-B593-C1D60F870FFD Q38838357-EB9595D5-D1FF-40E3-8AB5-9F071B9A1D5B Q38875985-13AA6D7D-6E80-42A8-8426-BD18E3B0D4A0 Q38930381-135EE9AE-31DB-4D9D-A5F0-397966EBD9E4 Q39888234-A533639E-E5EB-41F7-942E-55063AF0E8CB Q41067511-46FE2BD0-EC19-4EA5-A421-F7FF4F99ADEF Q41339458-4B2DA18C-AEB3-4CE1-B3BD-036B8B5CC037 Q41571663-25CE8443-1187-426F-B3FB-8B74E1879E9B Q41886148-2D2A7C3E-FA25-4712-A94A-EDB5C96B7B8C Q42697732-971EEA27-A77D-4DE0-AF52-E38C27FC869D Q46149223-792E7435-89D7-4413-9F8F-6BF02A390EB2 Q47186490-E449DA15-18AF-46CC-9389-AFFFF6B1A9D0

P2860

Molecular tumor board: the University of California-San Diego Moores Cancer Center experience.

http://www.wikidata.org/entity/Q33699594

description

2014 nî lūn-bûn

@nan

2014 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Molecular tumor board: the Uni ...... ores Cancer Center experience.

@ast

Molecular tumor board: the Uni ...... ores Cancer Center experience.

@en

type

label

Molecular tumor board: the Uni ...... ores Cancer Center experience.

@ast

Molecular tumor board: the Uni ...... ores Cancer Center experience.

@en

prefLabel

Molecular tumor board: the Uni ...... ores Cancer Center experience.

@ast

Molecular tumor board: the Uni ...... ores Cancer Center experience.

@en

P1433

Q33699594-E76E0C4D-9720-4075-95AA-11B883B34756

P1476

Q33699594-C65AB13F-4095-47C2-A119-37F030AD4242

P2093

Q33699594-0CCC66F1-035C-4AB1-B6B9-3DAA8DF76604

Q33699594-1EE28A86-1B20-4681-8FDA-A9C012D9BB98

Q33699594-29DCBC4C-31AF-47F7-BB7F-52B289C22756

Q33699594-32669E37-B550-4AF6-A92B-1162FA3C9C31

Q33699594-335B50F1-C476-4D99-AA8C-D8F742CAA937

Q33699594-63CCEC2C-12F4-44CB-AEF6-28B8ED68C11D

Q33699594-70EBBD0E-0413-4F85-B0B2-FB18869B02AD

Q33699594-8036218D-701C-4756-A912-4E056CC34E4E

Q33699594-82273366-4C72-48A8-AC4E-A38AA4AE5CAA

Q33699594-99CAF968-0E43-460B-B593-4DA87C5AD91A

P2860

Q33699594-09040819-7613-4CAE-83E7-5F47F2CA3423

Q33699594-099603AC-CA51-43F9-B09A-568A664BF817

Q33699594-0A4933F0-7788-4FAE-96F7-26CB089B0EB3

Q33699594-0E91C94B-623E-4D12-81B6-7FF10A7ACA04

Q33699594-141A431C-A78A-4C82-AB26-AEDCD6C2B3AF

Q33699594-16EC92C3-0773-4590-AA16-2CC59431F638

Q33699594-21F8936E-C430-4A64-AB40-5F82C272A70C

Q33699594-2383DB63-CF50-4835-ABBF-208B0F2F0160

Q33699594-2EF3152E-230A-46BE-B3F0-41984AE99235

Q33699594-35593D10-572C-45FB-AE37-988BDDFB7159

P304

Q33699594-68C7F64A-855D-40CA-8951-A0780C25C789

P31

Q33699594-FCA36B25-549D-438B-AE17-E4AB82B29E1F

P356

Q33699594-A8907C36-2A2D-46A6-ADBD-2A2CD6EF6414

P433

Q33699594-61921B38-E82B-476F-87FE-A10BF7515F0A

P478

Q33699594-3B0C0338-1A7F-430D-9286-70AB8F8FFF38

P50

Q33699594-88A0C018-1CDA-4F98-BB42-BF47E0CA8D4A

Q33699594-A008F96D-55C2-4589-A395-1807544F1483

P577

Q33699594-E80C9B07-914D-471B-B041-18A7D652AA6B

P5875

Q33699594-D8177886-D46A-452B-8A69-804CE293F675

P698

Q33699594-7CE6CCC3-06EE-4B8A-80F1-7E6D81E11793

P921

Q33699594-CE15582E-D754-4779-AAFE-A8568AD2F787

P932

Q33699594-A2B91A8F-F4EB-4440-BA19-824DF585A6D6

P356

THEONCOLOGIST.2013-0405

P1433

P1476

Molecular tumor board: the Uni ...... ores Cancer Center experience.

@en

P2093

Alice C Coutinho

http://www.w3.org/2001/XMLSchema#string

Barbara A Parker

http://www.w3.org/2001/XMLSchema#string

Brian Datnow

http://www.w3.org/2001/XMLSchema#string

Gregory A Daniels

http://www.w3.org/2001/XMLSchema#string

Haydee Ojeda-Fournier

http://www.w3.org/2001/XMLSchema#string

Lyudmila A Bazhenova

http://www.w3.org/2001/XMLSchema#string

Nicholas J Webster

http://www.w3.org/2001/XMLSchema#string

Paul T Fanta

http://www.w3.org/2001/XMLSchema#string

Richard B Schwab

http://www.w3.org/2001/XMLSchema#string

Rupa Subramanian

http://www.w3.org/2001/XMLSchema#string

P2860

Initial sequencing and analysis of the human genome

Hallmarks of Cancer: The Next Generation

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Targeted therapy for HER2 positive breast cancer

The genetic basis for cancer treatment decisions

Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

P304

631-636

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1634/THEONCOLOGIST.2013-0405

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P50

Razelle Kurzrock

Maria Schwaederle

P577

2014-05-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262071332

http://www.w3.org/2001/XMLSchema#string

P698

24797821

http://www.w3.org/2001/XMLSchema#string

P921

P932

4041669

http://www.w3.org/2001/XMLSchema#string